Showing 961-970 of 10242 results for "".
Beyond SPF: Protecting the Skin
https://practicaldermatology.com/topics/skin-cancer-photoprotection/beyond-spf-protecting-the-skin-/18535/In addition to protecting the skin from sun damage, it's becoming increasingly important to consider pollution's role in skin aging. Arianne Shadi Kourosh, MD, and Rebecca Kazin, MD discuss the need for a well tailored regimen and what to look for in sun protection, barrier protection, cleaners, anAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisWin Recognition for Your Practice with Strong Online Content
https://practicaldermatology.com/topics/practice-management/win-recognition-for-your-practice-with-strong-online-content/21095/In a crowded online space, you need an effective content strategy to earn attention and recognition from your target audience on a consistent basis.SRT100: Innovating Topical Radiation Therapy for Skin Cancers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/srt100-innovating-topical-radiation-therapy-for-skin-cancers/19041/The United States has become one of the chief areas of non-melanoma as well as melanoma skin cancer. One of the first treatments that was invented by dermatologists has been the use of radiation therapy for skin cancer. George Miller McKee, who is the father of many of the treatments of both melanoRestylane Lyft Approved, Analyzing New Quality of Life Data
https://practicaldermatology.com/series/dermwire-tv/dermwire-restylane-lyft-approved-analyzing-new-quality-of-life-data--ibalorid/18878/Restylane Lyft from Galderma approved for mid face volume enhancement, New data analyzes significance of patient quality of life in diseases like psoriasis and atopic dermatitis, Merz North America establishes new headquarters in Raleigh, NC, and Boston unveils free sunscreen dispensers.Implementing Skincare Solutions in Practice
https://practicaldermatology.com/topics/practice-management/implementing-skincare-solutions-in-practice/18902/Leslie Baumann, MD, FAAD discusses the challenges of offering effective skincare recommendations to patients and shares some of the practical solutions she has implemented in her practice. The author of "The Skin Type Solution," describes how she chooses skincare for each individual patient and giveKythera's Kybella Approved; ASLMS Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-kythera-s-kybella-approved-aslms-update/18925/FDA Approves Kythera's Kybella (ATX-101 or deoxycholic acid) injection for reduction of sub mental fullness or double chin. ASLMS Recognizes women in device-based medicine (Women in Energy-based Devices). Deka and Syneron get new clearances. ASDS Launches Skin Cancer PSAs, and Foamix sells shares.The Importance of Skincare
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-importance-of-skincare/19035/Whether patients want lasers, injectables, Botox, or cosmeceuticals, they need guidance on proper skincare to prevent wrinkles and skin cancer, says Dina Anderson, MD, FAAD. Patients need to learn about antioxidants, free radicals, and the effects of smoking.SEO Playbook: On-Page Factors
https://practicaldermatology.com/topics/practice-management/seo-playbook-on-page-factors/18994/Internet marketing is constantly changing--especially when it comes to SEO. Learn how on-page factors like Content, HTML, and architecture affect SEO and the marketing value of your practice website.DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's lates